Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

quote:

Dekkie schreef op 19 november 2018 18:55:

[...]
Alsjeblieft he Jules. Ze moeten het niet helemaal opnieuw gaan uitvinden hoor.
Beetje objectief alsjeblieft.

quote:

Dekkie schreef op 19 november 2018 18:58:

Wat ik vreemd vind is dat de shorters de laatste weken weinig tot niets met de koers te maken hebben. Er is een andere partij aan het spelen met de koers. Eentje die genoeg aandelen bezit om dit te doen.
Is er een partij die net onder de meldinggrens zit en die nu de koers manipuleert.
Dit kunnen we niet zien toch ?????

quote:

De Monitor schreef op 19 november 2018 18:23:

[...]

Je begint te brabbelen antop, wat is er aan de hand? Met de beste wil van de wereld, niemand snapt wat je nu weer bedoelt..

quote:

Techspec schreef op 19 november 2018 19:00:

[...]

Ik denk dat jij de enigste bent.....lol

quote:

Techspec schreef op 19 november 2018 19:00:

[...]

Ik denk dat jij de enigste bent.....lol

quote:

Dekkie schreef op 19 november 2018 18:58:

Wat ik vreemd vind is dat de shorters de laatste weken weinig tot niets met de koers te maken hebben. Er is een andere partij aan het spelen met de koers. Eentje die genoeg aandelen bezit om dit te doen.
Is er een partij die net onder de meldinggrens zit en die nu de koers manipuleert.
Dit kunnen we niet zien toch ?????

quote:

3 € Pharming schreef op 19 november 2018 18:59:

Profylaxe is nu helemaal niet zo belangrijk, het gaat om de toedieningsvorm.

Verwachting is dat ze in in 2024 2e speler op deze markt zijn met omzet van 640 miljoen Euro

Als een van de blockbusters dan ook op d3 markt zijn wordt het gigantisch....

quote:

3 € Pharming schreef op 19 november 2018 18:15:

[...]

Wat een onzin!

Kaspositie nam toe tot € 72,2 miljoen (na terugbetaling van schulden met € 7,5 miljoen) voor investering in belangrijke groeifactoren.

De positieve cashflows tijdens het derde kwartaal van 2018 hielden verband met de hogere inkomsten bovenop de benodigde kasmiddelen voor kosten en terugbetaling van de eerste driemaandelijkse tranche van € 7,5 miljoen van de hoofdsom van de uitstaande lening van de Onderneming, inclusief bijbehorende vergoedingen. Dit resulteerde in een toename van de kaspositie tot € 72,2 miljoen, vergeleken met € 66,9 miljoen op 30 juni 2018 (€ 38,6 miljoen op 30 september 2017). Hoezo onzin Hoelang zit jij dan al in pharming als je dit onzin noemt of heb je ook al een te roze bril op hoe kom jij aan 72 miljoen aan schulden,,,, eh,,,, ik bedoel kaspositie
Man man laat toch deze onzin,,, verkoop niet dat het plotseling een miljoenen bedrijf is geworden dat op rozen zit want die doornen kunnen pijnlijk zijn!!!
Trouwens,, wat zou De vries moeten melden?

quote:

LL schreef op 19 november 2018 19:02:

ORLANDO, Fla., Nov. 19, 2018 /PRNewswire/ -- Patients with certain rare, chronic and complex conditions can now obtain the medications that may improve or save their lives from AllianceRx Walgreens Prime, a leading central specialty and home delivery pharmacy.

The hard-to-find drugs, called limited distribution drugs, treat such rare conditions as metastatic breast cancer, chronic liver disease, metastatic non-small cell lung cancer, and hereditary angioedema, to name a few.

The drugs now available for AllianceRx Walgreens Prime patients include:

Doptelet® (avatrombopag) is used to treat thrombocytopenia (low blood platelet count) in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. Manufactured by Dova Pharmaceuticals, this is the first in its class approved by the Food and Drug Administration for this use.
Galafold™ (Migalastat) is the first oral medicine for Fabry disease, a rare, progressive genetic disorder characterized by a defective gene that causes an enzyme deficiency and impacts the kidneys. Manufactured by Amicus Therapeutics, Galafold is the first new therapy approved to treat adult patients with Fabry disease and an amenable galatosidase alpha gene (GLA) variant in the United States in more than 15 years.
Revcovi™ (elapegademase-lvlr), manufactured by Leadiant Biosciences, Inc., treats adenosine deaminase severe combined immune deficiency (ADA-SCID) affecting children and adults. ADA-SCID is caused by a deficiency in the ADA enzyme that is fatal if left untreated. Patients affected by ADA-SCID have compromised immune systems that leave them unprotected from infection-producing bacteria, viruses, and fungi.
Ruconest® (C1 esterase inhibitor [recombinant]), distributed by Pharming Healthcare Inc., is an intravenously infused medicine used to treat acute angioedema (rapid swelling beneath the skin) attacks in adults and adolescents with hereditary angioedema (HAE). HAE, which can be life threatening, is caused by the lack of or dysfunction of a protein called C1 esterase inhibitor, which leads to repeated attacks of swelling in the extremities, abdominal, face, genitals, and/or larynx.
Talzenna™ (talazoparib), manufactured by Pfizer, is used to treat patients who have a certain type of breast cancer (human epidermal growth factor receptor 2 [HER2]-negative), an abnormal inherited BRCA gene, and whose cancer has spread to other parts of the body (locally advanced or metastatic).
Vizimpro® (dacomitnib) treats non-small cell lung cancer that has spread to other parts of the body (metastatic). Also manufactured by Pfizer, Vizimpro is used as a first-line treatment if tumors have certain types of abnormal epidermal growth factor receptor genes.
Zavesca® (miglustat) is used alone to treat adults with mild-to-moderate type 1 Gaucher disease, a genetic condition in which the body lacks the enzyme needed to break down certain fatty materials (lipids). Zavesca is used only in people who cannot be treated with enzyme replacement therapy.

"In our ongoing support of patients with chronic, complex conditions and rare diseases, these additions make it easier for patients to get the medications they need," said Joel Wright, chief executive officer for AllianceRx Walgreens Prime. "While the FDA's approval of these medications supports our purpose of providing hope and care for better tomorrows, access to medication is just part of our treatment approach. Our pharmacists use an integrated care management program to deliver comprehensive and collaborative care for patients throughout their care journey."

About AllianceRx Walgreens Prime
AllianceRx Walgreens Prime (alliancerxwp.com) is a specialty and home delivery pharmacy that strives to provide exceptional care throughout a patient's treatment journey with the medications they need every day. Formed in 2017 through a collaboration between Walgreens, one of the nation's largest chain drug stores, and Prime Therapeutics, a leading pharmacy benefit manager, the company offers tools and resources for patients, providers and health plans to deliver the optimal health outcomes. The company is headquartered in Orlando, Fla. and its pharmacies are accredited by several national pharmacy accreditation services.

Media Contact
Adrienne Foley | adrienne.foley@alliancerxwp.com | 612.777.6259

SOURCE AllianceRx Walgreens Prime

bron: www.prnewswire.com/news-releases/addi...

buy low sell high

quote:

De Monitor schreef op 19 november 2018 19:04:

[...]

Ik ben inderdaad zeer enig. Ben verbaasd dat zelfs jij me enig vindt..

quote:

LL schreef op 19 november 2018 19:02:

ORLANDO, Fla., Nov. 19, 2018 /PRNewswire/ -- Patients with certain rare, chronic and complex conditions can now obtain the medications that may improve or save their lives from AllianceRx Walgreens Prime, a leading central specialty and home delivery pharmacy.

The hard-to-find drugs, called limited distribution drugs, treat such rare conditions as metastatic breast cancer, chronic liver disease, metastatic non-small cell lung cancer, and hereditary angioedema, to name a few.

The drugs now available for AllianceRx Walgreens Prime patients include:

Doptelet® (avatrombopag) is used to treat thrombocytopenia (low blood platelet count) in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. Manufactured by Dova Pharmaceuticals, this is the first in its class approved by the Food and Drug Administration for this use.
Galafold™ (Migalastat) is the first oral medicine for Fabry disease, a rare, progressive genetic disorder characterized by a defective gene that causes an enzyme deficiency and impacts the kidneys. Manufactured by Amicus Therapeutics, Galafold is the first new therapy approved to treat adult patients with Fabry disease and an amenable galatosidase alpha gene (GLA) variant in the United States in more than 15 years.
Revcovi™ (elapegademase-lvlr), manufactured by Leadiant Biosciences, Inc., treats adenosine deaminase severe combined immune deficiency (ADA-SCID) affecting children and adults. ADA-SCID is caused by a deficiency in the ADA enzyme that is fatal if left untreated. Patients affected by ADA-SCID have compromised immune systems that leave them unprotected from infection-producing bacteria, viruses, and fungi.
Ruconest® (C1 esterase inhibitor [recombinant]), distributed by Pharming Healthcare Inc., is an intravenously infused medicine used to treat acute angioedema (rapid swelling beneath the skin) attacks in adults and adolescents with hereditary angioedema (HAE). HAE, which can be life threatening, is caused by the lack of or dysfunction of a protein called C1 esterase inhibitor, which leads to repeated attacks of swelling in the extremities, abdominal, face, genitals, and/or larynx.
Talzenna™ (talazoparib), manufactured by Pfizer, is used to treat patients who have a certain type of breast cancer (human epidermal growth factor receptor 2 [HER2]-negative), an abnormal inherited BRCA gene, and whose cancer has spread to other parts of the body (locally advanced or metastatic).
Vizimpro® (dacomitnib) treats non-small cell lung cancer that has spread to other parts of the body (metastatic). Also manufactured by Pfizer, Vizimpro is used as a first-line treatment if tumors have certain types of abnormal epidermal growth factor receptor genes.
Zavesca® (miglustat) is used alone to treat adults with mild-to-moderate type 1 Gaucher disease, a genetic condition in which the body lacks the enzyme needed to break down certain fatty materials (lipids). Zavesca is used only in people who cannot be treated with enzyme replacement therapy.

"In our ongoing support of patients with chronic, complex conditions and rare diseases, these additions make it easier for patients to get the medications they need," said Joel Wright, chief executive officer for AllianceRx Walgreens Prime. "While the FDA's approval of these medications supports our purpose of providing hope and care for better tomorrows, access to medication is just part of our treatment approach. Our pharmacists use an integrated care management program to deliver comprehensive and collaborative care for patients throughout their care journey."

About AllianceRx Walgreens Prime
AllianceRx Walgreens Prime (alliancerxwp.com) is a specialty and home delivery pharmacy that strives to provide exceptional care throughout a patient's treatment journey with the medications they need every day. Formed in 2017 through a collaboration between Walgreens, one of the nation's largest chain drug stores, and Prime Therapeutics, a leading pharmacy benefit manager, the company offers tools and resources for patients, providers and health plans to deliver the optimal health outcomes. The company is headquartered in Orlando, Fla. and its pharmacies are accredited by several national pharmacy accreditation services.

Media Contact
Adrienne Foley | adrienne.foley@alliancerxwp.com | 612.777.6259

SOURCE AllianceRx Walgreens Prime

bron: www.prnewswire.com/news-releases/addi...

[b]buy low sell

quote:

Jopie1962 schreef op 19 november 2018 19:00:

[...]

Die 'partij', dat zijn de particulieren tesamen.

quote:

3 € Pharming schreef op 19 november 2018 19:04:

[...]

Als de aandelen rondgepompt worden hoeven maar een aantal particulieren erin te trappen en de koers gaat omlaag.Eind van de dag hebben de shorters dezelfde hoeveelheid aantallen aandelen en is de koers omlaag.

quote:

Sjaak60 schreef op 19 november 2018 19:11:

Morgen nog maar uitbreiden met Pharming aandelen, betaal ik tenminste veel minder vermogensbelasting.

quote:

Fortuinlijk schreef op 19 november 2018 19:13:

[...]

Precies, wij als particulieren helpen zelf de koers naar de Kl.t.n.

Paniekverkopers verkopen en slimme handelaren kopen bij